Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938792 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 189
- Enrollment target
NCT03938792 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 189 participants.
The verdict
NCT03938792, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 189 participants
- Enrollment target
Study Summary
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
Interventions
- DRUG PF-06741086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2025-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03938792
The ClinicalTrials.gov registry entry for NCT03938792 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06741086 is the first listed.
NCT03938792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03938792 about?
NCT03938792 is a clinical study titled "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B". Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhi...
What is the current status of trial NCT03938792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 189 participants. The study started on 2020-03-09. Estimated completion is 2025-04-29.
What interventions are being tested in trial NCT03938792?
The interventions under investigation include: PF-06741086 (DRUG).
Who is sponsoring clinical trial NCT03938792?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.